{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:34Z","timestamp":1794047434917,"version":"4.8.0"},"reference-count":26,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the combination of weekly carfilzomib 70 mg\/m2, cyclophosphamide and dexamethasone (KCd) was compared to carfilzomib and dexamethasone (Kd) in relapsed\/refractory multiple myeloma (RRMM) after 1-3 prior lines (PL). One hundred and ninety-seven patients were included and randomized 1:1 to receive KCd (97 patients) or Kd (100 patients) in 28-day cycles until progressive disease or unacceptable toxicity occurred. Patient median age was 70 years, and the median number of PL was one (range, 1-3). More than 90% of patients had previously been exposed to proteasome inhibitors, approximetely 70% to immunomodulators, and approximetely 50% were refractory to their last line (mainly lenalidomide) in both groups. After a median follow-up of 37 months, median progression-free survival (PFS) was 19.1 and 16.6 months in KCd and Kd, respectively (P=0.577). Of note, in the post hoc analysis of the lenalidomide-refractory population, the addition of cyclophosphamide to Kd resulted in a significant benefit in terms of PFS: 18.4 versus 11.3 months (hazard ratio =1.7, 95% confidence interval: 1.1-2.7; P=0.043). The overall response rate and the percentage of patients who achieved complete response was around 70% and 20% in both groups. The addition of cyclophosphamide to Kd did not result in any safety signal, except for severe infections (7% vs. 2%). In conclusion, the combination of cyclophosphamide with Kd 70 mg\/m2 weekly does not improve outcomes as compared with Kd alone in RRMM after 1-3 PL, but a significant benefit in PFS was observed with the triplet combination in the lenalidomide-refractory population. The administration of weekly carfilzomib 70 mg\/m2 was safe and convenient, and, overall, the toxicity was manageable in both arms.<\/jats:p>","DOI":"10.3324\/haematol.2022.282490","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T07:44:19Z","timestamp":1682581459000},"page":"2753-2763","source":"Crossref","is-referenced-by-count":14,"title":["Randomized phase II study of weekly carfilzomib 70 mg\/m&lt;sup&gt;2&lt;\/sup&gt; and dexamethasone with or without cyclophosphamide in relapsed and\/or refractory multiple myeloma patients"],"prefix":"10.3324","volume":"108","author":[{"given":"Borja","family":"Puertas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Clavero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"R\u00edos-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rey-Bua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Pilar","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Dourdil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"De Arriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"P\u00e9rez-de-Oteyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel T.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Garc\u00eda-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"52769","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5):2516-2520.","DOI":"10.1182\/blood-2007-10-116129"},{"key":"52770","doi-asserted-by":"crossref","unstructured":"Muchtar E, Gertz MA, Magen H. A practical review on carfilzomib in multiple myeloma. Eur J Haematol. 2016; 96(6):564-577.","DOI":"10.1111\/ejh.12749"},{"key":"52771","doi-asserted-by":"crossref","unstructured":"Papadopoulos KP, Siegel DS, Vesole DH. Phase I study of 30-minute infusion of car filzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and\/or refractory multiple Myeloma. J Clin Oncol. 2015; 33(7):732-739.","DOI":"10.1200\/JCO.2013.52.3522"},{"key":"52772","doi-asserted-by":"crossref","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2):142-152.","DOI":"10.1056\/NEJMoa1411321"},{"key":"52773","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Palumbo A. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17(1):27-38.","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"52774","doi-asserted-by":"crossref","unstructured":"Berenson JR, Cartmell A, Bessudo A. CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016; 127(26):3360-3368.","DOI":"10.1182\/blood-2015-11-683854"},{"key":"52775","doi-asserted-by":"crossref","unstructured":"Moreau P, Mateos MV, Berenson JR. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018; 19(7):953-964.","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"52776","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017; 18(10):1327-1337.","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"52777","doi-asserted-by":"crossref","unstructured":"Kropff M, Bisping G, Schuck E. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007; 138(3):330-337.","DOI":"10.1111\/j.1365-2141.2007.06656.x"},{"key":"52778","doi-asserted-by":"crossref","unstructured":"Fu W, Delasalle K, Wang J. Bortezomibcyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol. 2012; 35(6):562-565.","DOI":"10.1097\/COC.0b013e31822043f6"},{"key":"52779","doi-asserted-by":"crossref","unstructured":"de Waal EGM, de Munck L, Hoogendoorn M. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015; 171(5):720-725.","DOI":"10.1111\/bjh.13653"},{"key":"52780","doi-asserted-by":"crossref","unstructured":"Kropff M, Vogel M, Bisping G. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017; 96(11):1857-1866.","DOI":"10.1007\/s00277-017-3065-z"},{"key":"52781","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"52782","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Corral L, Guti\u00e9rrez NC, Vidriales MB. The Progression from MGUS to smoldering myeloma and eventually to multiple myeloma Involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011; 17(7):1692-1700.","DOI":"10.1158\/1078-0432.CCR-10-1066"},{"key":"52783","doi-asserted-by":"crossref","unstructured":"Fonseca R, Bergsagel PL, Drach J. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23(12):2210-2221.","DOI":"10.1038\/leu.2009.174"},{"key":"52784","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-e548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"52785","doi-asserted-by":"crossref","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017; 31(10):2094-2103.","DOI":"10.1038\/leu.2017.29"},{"key":"52786","doi-asserted-by":"crossref","unstructured":"Yong KL, Hinsley S, Auner HW. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). Haematologica. 2021; 106(10):2694-2706.","DOI":"10.3324\/haematol.2021.278399"},{"key":"52787","doi-asserted-by":"crossref","unstructured":"Venner CP, LeBlanc R, Sandhu I. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed\/refractory multiple myeloma: final results from the MCRN D003\/ MYX .1 single arm phase II trial. Am J Hematol. 2021; 96(5):552-560.","DOI":"10.1002\/ajh.26147"},{"key":"52788","doi-asserted-by":"crossref","unstructured":"Moreau P, Joshua D, Chng WJ. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017; 31(1):115-122.","DOI":"10.1038\/leu.2016.186"},{"key":"52789","doi-asserted-by":"crossref","unstructured":"Mateos MV, Sonneveld P, Hungria V. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020; 20(8):509-518.","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"52790","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(6):801-812.","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"52791","doi-asserted-by":"crossref","unstructured":"Richardson PG, Oriol A, Beksac M. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(6):781-794.","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"52792","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Quach H, Mateos MV. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022; 23(1):65-76.","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"52793","doi-asserted-by":"crossref","unstructured":"Moreau P, Dimopoulos MAC, Mikhael J. VP5-2022: updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM). Ann Oncol. 2022; 33(6):664-665.","DOI":"10.1016\/j.annonc.2022.04.013"},{"key":"52794","doi-asserted-by":"crossref","unstructured":"Moreau P, Dimopoulos MA, Mikhael J. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021; 397(10292):2361-2371.","DOI":"10.1016\/S0140-6736(21)00592-4"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282490\/75594","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282490\/76106","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11068\/75594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:59Z","timestamp":1794045839000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282490","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}